Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Innate Pharma

IPHA
Current price
2.44 USD -0.02 USD (-0.81%)
Last closed 2.35 USD
Sector Healthcare
Industry Biotechnology
Exchange PINK
Capitalization 202 197 600 USD
Yield for 12 month +8.14 %
Week
Month
Year
IPHA
21.11.2021 - 28.11.2021

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. Address: 117, Avenue de Luminy, Marseille, France, 13009

Analytics

WallStreet Target Price

P/E ratio

Dividend Yield

Current Year

+54 633 183 USD

Last Year

+13 330 589 USD

Current Quarter

+22 121 162 USD

Last Quarter

+6 649 886 USD

Current Year

+54 633 183 USD

Last Year

+13 330 589 USD

Current Quarter

+4 812 418 USD

Last Quarter

-8 047 111 USD

Key Figures IPHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -19 191 000 USD
Operating Margin TTM -0.99 %
PE Ratio
Return On Assets TTM -6.6 %
PEG Ratio
Return On Equity TTM -71.91 %
Wall Street Target Price
Revenue TTM 52 283 000 USD
Book Value 0.72 USD
Revenue Per Share TTM 0.65 USD
Dividend Share
Quarterly Revenue Growth YOY -11.8 %
Dividend Yield
Gross Profit TTM 57 674 000 USD
Earnings Share -0.86 USD
Diluted Eps TTM -0.86 USD
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY -74.7 %
Profit Margin -119.9 %

Dividend Analytics IPHA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IPHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IPHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.0258
Price Sales TTM 3.2659
Enterprise Value EBITDA -5.4266
Price Book MRQ 1.4757

Financials IPHA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IPHA

For 52 weeks

2.16 USD 3.75 USD
50 Day MA 2.59 USD
Shares Short Prior Month
200 Day MA 2.91 USD
Short Ratio
Shares Short
Short Percent